DCVC Opportunity Fund II GP, LLC — Q2 2025 13F-HR

← DCVC Opportunity Fund II GP, LLC

Q2 2025 · 13F-HR

DCVC Opportunity Fund II GP, LLCholdings as filed

Filed 2025-08-14 · accession 0001104659-25-078025

$115.3M

Reported value

Positions

2025-06-30

Period end

View analyzed profile →PRO

The Brief · DCVC Opportunity Fund II GP, LLC · Q2 2025

AI · grounded in 13F

DCVC Opportunity Fund II GP, LLC established a new position in Rocket Lab Corp RKLB valued at $95.26M. The fund also added Recursion Pharmaceuticals, Inc. RXRX to its portfolio with a new position of $19.99M. These two holdings comprise the fund's total AUM of $115.25M.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
773121108	RKLB	Rocket Lab Corp	$95.3M	82.7%	2,663,139	Common	SOLE
75629V104	RXRX	Recursion Pharmaceuticals, Inc.	$20.0M	17.3%	3,951,141	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.